

**Dosimetric Comparisons of Volumetric Modulated Arc Therapy with Three-Dimensional Conformal Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer**

Takesumi Ozawa\*, Keiichiro Koiwai, Hirohide Matsushita, and Masumi Kadoya

Department of Radiology, Shinshu University School of Medicine

Keywords: non-small cell lung cancer, volumetric modulated arc therapy, three-dimensional conformal radiation therapy, treatment planning comparison

Running title: Comparison of VMAT with 3D-CRT for NSCLC

Total number of pages: 7 pages.

Total number of tables: 2 tables.

**The number of reprints: 80**

\*Corresponding author: Takesumi Ozawa

Tel: +(81)-263-37-2650; Fax: +(81)-263-37-3087; E-mail: tozawa@shinshu-u.ac.jp

Department of Radiology, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto,

390-8621 Japan.

## **Abstract**

**Purpose:** To evaluate the dosimetric differences between volumetric modulated arc therapy (VMAT) and three-dimensional conformal radiation therapy (3D-CRT) for locally advanced non-small cell lung cancer (NSCLC).

**Materials and methods:** A planning study was performed with the data of 17 patients with inoperable NSCLC who actually underwent definitive radiotherapy. VMAT and 3D-CRT plans were created for each patient. The primary objectives of these plans were to prescribe 60 Gy in 30 fractions to 95% of the planning target volume and to limit the dose delivered to the spinal cord to less than 50 Gy. The secondary objectives were to keep the doses delivered to other risk organs as low as possible.

**Results:** The 3D-CRT plans for two patients did not achieve the primary objectives, although they were achieved by the VMAT plans for these patients. In a comparison of the acceptable plans, the VMAT plans improved the dose conformity,  $V_{20}$  and mean dose of the lung, and  $V_{35}$  of the oesophagus. There were no significant differences in  $V_{10}$  or  $V_5$  of the lung, or the maximum dose and mean dose of the oesophagus.

**Conclusion:** The advantage of VMAT compared to 3D-CRT may facilitate appropriate use of VMAT for patients with locally advanced NSCLC.

【目的】 進行期非小細胞肺癌に対する根治的放射線治療として、三次元原体放射線治療 (3D-CRT) と強度変調回転放射線治療 (VMAT) による治療計画を行い、線量分布を比較・検討した。

【方法】 当院で進行期非小細胞肺癌に対する根治的放射線治療を計画した 17 症例を対象とした。各症例において VMAT と 3D-CRT による治療計画を行った。Primary objective として、計画標的体積の 95% に 60 Gy/30 分割を投与し、かつ脊髄の最大線量を 50 Gy 未満にすることとした。Secondary objective として、他のリスク臓器の線量を可能な限り低減することとした。

【結果】 3D-CRT では 17 例中 2 例で primary objective を達成できなかったが、VMAT では全例達成可能であった。双方の計画で達成できた 15 例の検討では、線量収束性や肺の V20 および平均線量、食道 V35 において VMAT の方が良好であった。肺低線量域や食道の最大線量および平均線量に有意差は認めなかった。

【結論】 3D-CRT に対する VMAT の優位性は、局所進行期肺癌に対する根治的放射線治療における VMAT の適切な利用を促進するかもしれない。

## I Introduction

Radiotherapy plays a key role in the treatment of inoperable locally advanced non-small cell lung cancer (NSCLC) <sup>1)</sup>. Although radiotherapy is recognized as the standard of care for advanced NSCLC, significant challenges remain regarding this therapy. The lungs are surrounded by critical organs, such as the spinal cord, oesophagus, and heart. Furthermore, the lung itself is vulnerable to radiation. Delivering the prescribed doses to the planning target volume (PTV) while preventing intolerable irradiation of the organs at risk (OAR) is often difficult to achieve. Although this dilemma has been partially resolved with the advent of three-dimensional conformal radiation therapy (3D-CRT), a number of problems remain. Intensity-modulated radiation therapy (IMRT) has been expected to solve some of these issues, and has recently been utilized in clinical settings <sup>2)-4)</sup>. Volumetric modulated arc therapy (VMAT) is an advanced form of IMRT that efficiently provides highly conformal dose distributions with rotation of the gantry. Several planning studies showed that VMAT, especially partial arc (PA)-VMAT, has some advantages compared with conventional IMRT in the treatment of locally advanced NSCLC <sup>5)6)</sup>. However, there have been few studies related to the benefits of VMAT compared with 3D-CRT in consecutive patients. In this study, we investigated the dosimetric differences between VMAT and 3D-CRT plans and evaluated whether VMAT is more beneficial than 3D-CRT in the treatment of locally advanced NSCLC.

## II Materials and Methods

The institutional review board of our hospital approved this retrospective study, and the requirement to obtain informed consent from study patients was waived. Seventeen patients with inoperable locally advanced NSCLC who underwent definitive radiotherapy between January 2013 and August 2014 at our institution were selected for this study. The patient characteristics are listed in Table 1. All patients were staged by the 7th edition of the UICC-TNM staging system. Ten of 17 patients were staged as T4 or N3. Computed tomography (CT) images were acquired for radiation treatment planning in all patients. The entire thorax was scanned in the supine position with both arms raised above the head. Respiratory movement was evaluated with either four-dimensional CT images or breath-held CT images at inhaling and exhaling positions.

On those planning CT images, we newly contoured target volumes and OARs according to the following definitions. The gross tumour volume (GTV) was defined as the primary lesion that was macroscopically identifiable and lymph nodes > 1 cm in diameter. Fluorodeoxyglucose-positron emission tomography (FDG-PET) images were utilized for delineation of GTV when available. The GTV was delineated considering respiratory movement. The clinical target volume (CTV) enclosed the GTV with a margin of 0.5 – 1 cm. The PTV enclosed the CTV with a margin of 0.5 cm. The OARs consisted of the lung, spinal cord, oesophagus, and heart. Planning organ at-risk volumes (PRVs) were extended as 0.3 cm to the spinal cord, oesophagus, and heart. The lung PRV included both ipsi- and contralateral lungs, but the GTV was excluded.

Both 3D-CRT and the VMAT plans were created on the Eclipse treatment planning system (version 11; Varian Medical Systems, Palo Alto, CA, USA) with 10-MV photon beams. Doses were calculated with the anisotropic analytical algorithm. The 3D-CRT plans typically consisted of four beams arranged with anterior–posterior (AP) opposed beams and oblique off-cord opposed beams. The VMAT plans typically consisted of two partial coplanar arcs. Irradiation was avoided on the lateral sectors ( $40^\circ - 140^\circ$ ,  $220^\circ - 320^\circ$ ) to prevent excessive irradiation of the normal lung tissue.

The primary objectives of planning were to prescribe 60 Gy in 30 fractions to 95% of the PTV and to limit the dose delivered to the spinal cord PRV  $< 50$  Gy. The secondary objectives were to keep the doses delivered to other PRVs as low as possible. The dose–volume constraints for the PRVs were set as follows: lung PRV, volume receiving  $> 20$  Gy ( $V_{20}$ )  $< 35\%$  and mean lung dose (MLD)  $< 20$  Gy; oesophagus PRV, mean dose ( $D_{\text{mean}}$ )  $< 34$  Gy; heart PRV, volume receiving  $> 40$  Gy ( $V_{40}$ )  $< 80\%$ .

Plans in which both the primary and secondary objectives were achieved were considered acceptable.

To compare the VMAT with the 3D-CRT plans, the dose–volume histograms (DVHs) of the PTV and the PRVs were calculated in each plan. The homogeneity index (HI) and conformity index (CI) were computed from the data of DVH to assess the quality of planning. The HI was defined as the ratio of the maximum dose ( $D_{\text{max}}$ ) over the minimum dose ( $D_{\text{min}}$ ) in the PTV. Greater HI values indicated doses exceeding the prescription dose and a greater degree of dose heterogeneity in the PTV. The CI was defined as the ratio of the prescription-isodose volume over the PTV. Greater CI values indicated a greater volume of the prescription dose delivered outside the PTV.

The collected data were statistically analysed based on Wilcoxon's signed rank test using JMP (version 5.1.1; SAS Institute, Cary, NC, USA). In all analyses, a value of  $P < 0.05$  was considered to be significant.

### III Results

The primary objectives were not achieved in the 3D-CRT plans for two patients (Patients 3 and 14). Delivery of 60 Gy to 95% of the PTV could not be achieved within the limit of dose to the spinal cord PRV because their PTVs were near the spinal cord PRV and the off-cord fields could not encompass the entire PTVs. We were able to create acceptable VMAT plans with full arcs for these patients. In the remaining 15 patients, all of the created plans were considered acceptable. Further analyses were performed on the acceptable plans for these 15 patients.

Comparisons of the DVH-based parameters of the PA-VMAT with 3D-CRT plans for the 15 patients are shown in Table 2. The conformity of the dose distribution to the PTV was significantly improved in the PA-VMAT plans ( $P < 0.001$ ). On the other hand, the homogeneity of the dose distribution to the PTV was significantly better in the 3D-CRT plans ( $P = 0.041$ ). Compared with the 3D-CRT plans, the PA-VMAT plans significantly reduced the dose of  $V_{20}$  ( $P = 0.003$ ) and mean dose of the lung ( $P = 0.002$ ),  $V_{35}$  of the oesophagus ( $P = 0.033$ ), and  $V_{40}$  of the heart ( $P = 0.020$ ). There were no significant differences between 3D-CRT and PA-VMAT plans with regard to  $V_{10}$  ( $P = 0.258$ ) and  $V_5$  ( $P = 0.923$ ) of the lung.

## IV Discussion

This planning study was performed on the data of patients with inoperable NSCLC who underwent definitive radiotherapy at our institution. The majority of the patients were staged as T4 or N3, i.e. completely unresectable. This is thought to be the general case in clinical situations, so our study reflects the conditions in actual clinical practice. In this study, the 3D-CRT plans for two of 17 patients were considered unacceptable because the off-cord fields in the plans could not encompass the entire PTVs. The 3D-CRT plans were obviously inadequate for these cases, but the VMAT plans delivered sufficient dose to the PTV while maintaining the dose to the PRVs within acceptable levels.

In this study, the dose conformity was improved in the VMAT plans, although the dose heterogeneity increased. The dose distributions in IMRT/VMAT plans commonly have more hot and cold spots compared with 3D-CRT plans, which is not regarded as a serious problem, although efforts to evaluate and optimize is needed, if precise inspections confirm that the IMRT/VMAT plans are clinically acceptable <sup>7)</sup>.

Radiation pneumonitis (RP) is a life-threatening adverse event occurring in 13% – 37% of patients receiving thoracic radiotherapy for NSCLC <sup>8)</sup>. DVH parameters, especially  $V_{20}$  and MLD, have been accepted as predictors of RP after radiotherapy for lung cancer <sup>9)-12)</sup>. Other parameters, such as  $V_5$  and  $V_{10}$ , were also reported to be associated with RP <sup>13)14)</sup>. Our data showed that the VMAT plans resulted in better sparing of the lung, i.e. reducing  $V_{20}$  and MLD, compared with the 3D-CRT plans, while



suppressing expansion of low-dose areas in the lung. The efficiency of VMAT in sparing of the lung was consistent with previous studies comparing VMAT plans with conventional IMRT plans<sup>5)6)</sup>. We confirmed the superiority of VMAT to 3D-CRT, which has been utilized in actual clinical settings more frequently than conventional IMRT.

Radiation oesophagitis (RO) is a common acute and chronic toxicity, especially in the setting of concurrent chemoradiotherapy, and is known to adversely affect the quality of life (QOL) of patients<sup>15)</sup>. Several DVH parameters, such as  $V_{35}$ , were reported to be potentially relevant for prediction of RO<sup>16)17)</sup>. The present study indicated that VMAT plans potentially reduced the  $V_{35}$  of the oesophagus.

Although there are some uncertainties in predicting RO, reduction of the dose to the oesophagus with VMAT may improve the QOL of NSCLC patients treated with radiotherapy.

In our study, the median doses of the heart were quite low in both 3D-CRT and VMAT plans. This was attributed to the inclusion of only a few patients with left lower lobe tumour in our study population. Therefore, we cannot conclude that the difference in heart dose between 3D-CRT and VMAT plans observed in the present study is clinically significant.

Although reports of the clinical usefulness of IMRT/VMAT are still sparse<sup>18)-20)</sup>, several planning studies indicated the advantages of IMRT/VMAT in the treatment of locally advanced NSCLC<sup>2)5)6)21)</sup>. However, it is impractical to treat every patient with IMRT/VMAT as it usually requires more time for preparation than 3D-CRT. The dose verification and quality assurance required for IMRT/VMAT are

burdensome for medical staff, especially in understaffed institutions. Therefore, prioritizing patients should be considered. The results of the present study directly comparing VMAT plans with 3D-CRT plans represent meaningful information for such prioritization. Based on our findings, patients in whom off-cord fields in 3D-CRT plans cannot encompass their entire PTVs should be highly prioritized as candidates for VMAT.

This study had several limitations. First, we did not consider motion-reducing approaches, such as breath holding and respiratory gating, although the interplay effects may have only a small dosimetric impact on fractionated radiotherapy<sup>22)</sup>. The number of the patients was small, the locations of the tumours in the lung were biased, and plans created with 10-MV photon beams and lower-energy photon beams, which may improve the dose distribution of lung cancer treatment, were not tested due to the limitations of our radiation therapy equipment.

We demonstrated the advantages of VMAT plans compared to 3D-CRT plans for locally advanced NSCLC. These findings may facilitate appropriate usage of VMAT for such cases.

## V **Acknowledgements**

The authors are grateful to Mrs. I. Koiwai and Mrs. Y. Ogawa for technical assistance.

## References

- 1) Bezzak A, Temin S, Franklin G, Giaccone G, Govindan R, Johnson ML, Rimner A, Schneider BJ, Strawn J, Azzoli CG: Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. *J Clin Oncol* 33: 2100-2105, 2015
- 2) Liu HH, Wang X, Dong L, Wu Q, Liao Z, Stevens CW, Guerrero TM, Komaki R, Cox JD, Mohan R: Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. *International journal of radiation oncology, biology, physics* 58: 1268-1279, 2004
- 3) Bezzak A, Rumble RB, Rodrigues G, Hope A, Warde P: Intensity-modulated radiotherapy in the treatment of lung cancer. *Clinical oncology (Royal College of Radiologists (Great Britain))* 24: 508-520, 2012
- 4) Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW, Jr., Diehn M: A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. *International journal of radiation oncology, biology, physics* 88: 872-884, 2014
- 5) Jiang X, Li T, Liu Y, Zhou L, Xu Y, Zhou X, Gong Y: Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT). *Radiation oncology (London, England)* 6: 140, 2011
- 6) Rosca F, Kirk M, Soto D, Sall W, McIntyre J: Reducing the low-dose lung radiation for

central lung tumors by restricting the IMRT beams and arc arrangement. *Medical dosimetry* : official journal of the American Association of Medical Dosimetrists 37: 280-286, 2012

7) International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). ICRU report 83. *J ICRU* 10: 1-106, 2010

8) Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J: Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 71: 127-138, 2004

9) Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). *International journal of radiation oncology, biology, physics* 45: 323-329, 1999

10) Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, Lind PA: Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. *International journal of radiation oncology, biology, physics* 51: 650-659, 2001

11) Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, Kado T, Takada Y: Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. *International journal of radiation oncology, biology, physics* 55: 110-115, 2003

12) Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A: Radiation dose-volume effects in the

lung. International journal of radiation oncology, biology, physics 76: S70-76, 2010

13) Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki R:

Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). International journal of radiation oncology, biology, physics 66: 1399-1407, 2006

14) Tsujino K, Hashimoto T, Shimada T, Yoden E, Fujii O, Ota Y, Satouchi M, Negoro S,

Adachi S, Soejima T: Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9: 983-990, 2014

15) Pijls-Johannesma M, Houben R, Boersma L, Grutters J, Seghers K, Lambin P, Wanders R,

De Ruyscher D: High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 91: 443-448, 2009

16) Rose J, Rodrigues G, Yaremko B, Lock M, D'Souza D: Systematic review of dose-volume

parameters in the prediction of esophagitis in thoracic radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 91: 282-287, 2009

17) Huang EX, Bradley JD, El Naqa I, Hope AJ, Lindsay PE, Bosch WR, Matthews JW,

Sause WT, Graham MV, Deasy JO: Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients. International

journal of radiation oncology, biology, physics 82: 1674-1679, 2012

- 18) Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE: Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 87: 17-23, 2008
- 19) Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z: Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. *International journal of radiation oncology, biology, physics* 83: 332-339, 2012
- 20) Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R: Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. *International journal of radiation oncology, biology, physics* 68: 94-102, 2007
- 21) Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R: Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. *International journal of radiation oncology, biology, physics* 58: 1258-1267, 2004
- 22) Bortfeld T, Jiang SB, Rietzel E: Effects of motion on the total dose distribution. *Seminars in radiation oncology* 14: 41-51, 2004

**Table 1** Patient characteristics

Patient	TNM	Location	PTV (cm <sup>3</sup> )	T4/N3 descriptor
1	T4N0M0	Right lower lobe	216	Invasion to the heart
2	T4N2M0	Right upper lobe	853	Invasion to the great vessels
3	T4N1M0	Right upper lobe	581	Invasion to the vertebral body
4	T4N2M0	Left upper lobe	251	Invasion to the oesophagus
5	T1N2M0	Right upper lobe	147	
6	T3N3M0	Right upper lobe	481	Metastasis in the ipsilateral supraclavicular lymph nodes
7	T3N2M0	Right upper lobe	280	
8	T4N2M0	Left hilus	58	Invasion to the carina
9	T4N2M0	Left upper lobe	611	Invasion to the heart
10	T3N2M0	Right upper lobe	508	
11	T1N1M0	Right upper lobe	147	
12	T2N2M0	Left lower lobe	273	
13	T1N3M0	Left upper lobe	281	Metastasis in the ipsilateral supraclavicular lymph nodes
14	T4N3M0	Left upper lobe	776	Invasion to the mediastinum/ metastasis in the contralateral mediastinal lymph nodes
15	T4N0M0	Left hilus	89	Invasion to the carina
16	T2N1M0	Left lower lobe	262	
17	T2N1M0	Left upper lobe	240	

PTV, planning target volume.

**Table 2** Comparisons of dose distributions between VMAT and 3D-CRT plans

	Dose constraints	3D-CRT		VMAT		<i>P</i> -value
		Median	Range	Median	Range	
<b>PTV</b>						
	D <sub>mean</sub> (Gy)	63.7	62.6 – 64.6	63.7	62.5 – 64.9	0.916
	HI	1.27	1.20 – 1.70	1.50	1.25 – 5.34	0.041
	CI	2.04	1.54 – 2.93	1.33	1.08 – 2.05	< 0.001
<b>Lung</b>						
	V <sub>20</sub> (%) < 35	19.0	7.8 – 29.8	14.3	5.3 – 28.9	0.003
	MLD (Gy) < 20	9.7	4.5 – 17.1	8.8	3.7 – 17.2	0.002
	V <sub>10</sub> (%)	22.9	12.0 – 33.8	20.1	8.7 – 36.7	0.258
	V <sub>5</sub> (%)	31.0	15.8 – 44.2	27.9	13.6 – 48.5	0.923
<b>Esophagus</b>						
	D <sub>mean</sub> (Gy) < 34	15.8	1.5 – 23.0	15.1	1.4 – 22.7	0.182
	D <sub>max</sub> (Gy)	64.6	23.6 – 66.3	62.9	13.2 – 65.3	0.241
	V <sub>35</sub> (%)	22.7	0.0 – 36.3	20.6	0.0 – 30.0	0.033
<b>Heart</b>						
	V <sub>40</sub> (%) < 80	0.4	0.0 – 31.5	0.4	0.0 – 20.0	0.020

3D-CRT, three-dimensional conformal radiation therapy; VMAT, volumetric modulated arc therapy; PTV, planning target volume; MLD mean lung dose.